Invention Grant
- Patent Title: Low, immune enhancing, dose mtor inhibitors and uses thereof
-
Application No.: US15292088Application Date: 2016-10-12
-
Publication No.: US10004803B2Publication Date: 2018-06-26
- Inventor: Joan Mannick , David Glass , Leon Murphy
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Dechert LLP
- Agent Andrea L. C. Reid
- Main IPC: A61K39/39
- IPC: A61K39/39 ; A61K39/12 ; A61K39/00 ; A61K31/519 ; A61K31/4745 ; A61K31/436 ; A61K39/09 ; G01N33/68 ; A61K39/145 ; C12N7/00 ; A61K45/06
Abstract:
The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mTOR inhibition, for example, with low, immune enhancing, doses of an mTOR inhibitor, such as RAD001.
Public/Granted literature
- US20170281753A1 LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF Public/Granted day:2017-10-05
Information query
